Quantcast

Latest Valeant Pharmaceuticals Stories

2014-03-06 12:27:00

The pharmaceutical company is committed to donating a portion of its Medicis® and Obagi® product sales every quarter for a combined donation goal of $1 million in one year. NEW YORK, March 6, 2014 /PRNewswire/ -- Valeant Pharmaceuticals North America, LLC, today announced it has donated $250,000 to the National Coalition Against Domestic Violence (NCADV). The donation is a reflection of Valeant's ongoing support and commitment to the wellbeing of women, and is the first of four checks the...

2014-02-27 12:27:41

LONDON, Feb. 27, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Global Parkinson's Disease Market 2012-2016 TechNavio's analysts forecast the Global Parkinson's Disease market to grow at a CAGR of 1.67 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rise in the aging population. The Global Parkinson's Disease market has also been witnessing the transition toward using drugs that have new...

2014-02-05 16:28:03

LAVAL, Quebec, Feb. 5, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along with a slide presentation on Thursday, February 27, 2014 at 8:00 a.m. ET (5:00 a.m. PT) to discuss results for the 2013 fourth quarter and full year. The dial-in number to participate on this call is (877) 876-8393, confirmation code 68673247. International callers should dial (973)...

2014-02-03 08:27:23

LAVAL, Quebec, Feb. 3, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has entered into a definitive agreement under which Valeant will acquire PreCision Dermatology, Inc. for $475 million in cash, plus an additional $25 million payable upon the achievement of a sales-based milestone. PreCision develops and markets high quality dermatology products with leading products such as Locoid, Hylatopic, Clindagel, and...

2014-01-31 08:25:29

LAVAL, Quebec, Jan. 31, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has received approval from the Food and Drug Administration (FDA) for its Supplemental New Drug Application (sNDA) for Retin-A Micro (tretinoin) Gel microsphere 0.08% for the topical treatment of acne vulgaris. "We are very pleased that the FDA has approved our new strength of Retin-A Micro® as this gives health care providers and patients a new...

2014-01-23 16:25:32

LAVAL, Quebec, Jan. 23, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the completion of the previously announced transaction in which a wholly-owned subsidiary of Valeant Pharmaceuticals International ("VPI") would acquire Solta Medical, Inc. (NASDAQ: SLTM) ("Solta") at a price of $2.92 per share in cash, or approximately $250 million in the aggregate. On January 23, 2014, Valeant announced that it had...

2014-01-23 08:31:22

LAVAL, Quebec, Jan. 23, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced the expiration of the tender offer (the "Offer") by a subsidiary of Valeant Pharmaceuticals International ("VPI") to purchase all of the outstanding shares of Solta Medical, Inc. (NASDAQ: SLTM) ("Solta") for a price of $2.92 per share in cash, without interest (less any applicable withholding taxes). The Offer expired at midnight, New York...

2014-01-22 08:28:55

LAVAL, Quebec, Jan. 22, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that its board of directors has authorized a new securities repurchase program (the "Securities Repurchase Program"). Under the Securities Repurchase Program, which commenced on November 22, 2013, the Company may make purchases of up to $1.5 billion of its convertible notes, senior notes, common shares and/or other debt or shares that may be issued prior to...

2014-01-15 08:28:04

LAVAL, Quebec, Jan. 15, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced that the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") with respect to the previously announced tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for all of the outstanding shares of common stock of Solta Medical, Inc. (NASDAQ: SLTM) ("Solta") at a price of $2.92 per...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related